retatrutide biolongevity labs Stephen Schmidt

Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. @DrLaPook explains it's doing much more than what current medications can

20.85

★★★★☆4.6 (38)

White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration's (FDA) “compassionate use program.” Read more:

26.45

★★★★★4.7 (99)

Retatrutide vs Tirzepatide: Key Differences for Researchers

23.89

★★★★★4.3 (93)

Triple G pen 20 mg (Reta)

25.37

★★★★★4.3 (166)

Expanded Access vs. Right to Try: What Patients Need to Know » Triage Cancer®

24.41

★★★★★4.6 (230)

Retatrutide - “Triple G”

25.19

★★★★★4.5 (231)

Reports claim that a single well-connected patient received early access to Eli Lilly's experimental weight-loss drug, Retatrutide, through the FDA's compassionate use program before approval. The patient was reportedly 79 years old,

25.20

★★★★★4.8 (290)